The disappointing Q4 results and lower-than-expected revenue...

The disappointing Q4 results and lower-than-expected revenue forecast for the full year have negatively impacted Novavax's stock price. The company's ongoing financial struggles and cost-cutting measures, including a 30% headcount reduction, indicate a challenging outlook.